Janus Henderson Group PLC lowered its position in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 5.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,331,759 shares of the company’s stock after selling 227,413 shares during the period. Janus Henderson Group PLC owned 6.29% of Diplomat Pharmacy worth $89,711,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DPLO. Louisiana State Employees Retirement System grew its holdings in Diplomat Pharmacy by 0.6% during the second quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock valued at $263,000 after purchasing an additional 100 shares during the last quarter. Arizona State Retirement System grew its holdings in Diplomat Pharmacy by 0.9% during the second quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock valued at $337,000 after purchasing an additional 200 shares during the last quarter. Bank of Montreal Can grew its holdings in Diplomat Pharmacy by 3.0% during the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after purchasing an additional 340 shares during the last quarter. Texas Permanent School Fund grew its holdings in Diplomat Pharmacy by 1.5% during the second quarter. Texas Permanent School Fund now owns 31,890 shares of the company’s stock valued at $472,000 after purchasing an additional 470 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after purchasing an additional 480 shares during the last quarter. Hedge funds and other institutional investors own 72.48% of the company’s stock.

Several equities analysts have commented on the company. Leerink Swann upgraded Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a report on Monday. Deutsche Bank assumed coverage on Diplomat Pharmacy in a research report on Monday, December 4th. They issued a “buy” rating and a $22.00 price objective for the company. Robert W. Baird cut Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $18.00 in a research report on Thursday, November 16th. BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, Needham & Company LLC increased their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $20.72.

In other news, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $15.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at $30,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joel Saban bought 10,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $15.24 per share, with a total value of $152,400.00. Following the completion of the transaction, the president now owns 12,000 shares of the company’s stock, valued at $182,880. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 15,000 shares of company stock valued at $228,780. 30.20% of the stock is owned by company insiders.

Shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) opened at $19.82 on Friday. Diplomat Pharmacy, Inc. has a 12-month low of $12.25 and a 12-month high of $21.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market capitalization of $1,395.37, a P/E ratio of 26.31, a PEG ratio of 3.65 and a beta of 0.61.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the business earned $0.21 earnings per share. Diplomat Pharmacy’s revenue for the quarter was down 4.8% compared to the same quarter last year. sell-side analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/janus-henderson-group-plc-reduces-position-in-diplomat-pharmacy-inc-dplo/1765472.html.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.